New molecular targets in mantle cell lymphoma
- 30 November 2011
- journal article
- review article
- Published by Elsevier BV in Seminars in Cancer Biology
- Vol. 21 (5), 335-346
- https://doi.org/10.1016/j.semcancer.2011.09.008
Abstract
No abstract availableKeywords
This publication has 103 references indexed in Scilit:
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNature Medicine, 2011
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyThe Lancet Oncology, 2011
- Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signalingCellular Oncology, 2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2Nature, 2010
- Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblastsNature Genetics, 2009
- PI3 Kinase Signals BCR-Dependent Mature B Cell SurvivalCell, 2009
- Targeted and genome-scale strategies reveal gene-body methylation signatures in human cellsNature Biotechnology, 2009
- Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphomaCancer, 2008
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006